Global industry leaders join the Board of Directors

Søren Skou and Steve Van Kuiken have been elected to the Board of Directors of Controlant at the 2023 Annual General Meeting held on 16 June 2023, with Skou commencing his term as Board Director as of 1 January 2024. Skou and Van Kuiken bring extensive global industry experience to the Board, from the shipping and logistics industry, and the healthcare and technology industry respectively, strengthening the company’s leadership ahead of the next growth phase.  

Søren Skou 

Søren Skou is a globally recognized leader in shipping and logistics. Skou joins from A. P. Møller Maersk where he served as CEO from 2016 to 2022. During his tenure as CEO, Maersk transformed from a diversified conglomerate into a globally integrated USD 60Bn+ logistics company. He led Maersk through a business, digital, and culture transformation as well as positioning the company as a leader in decarbonization in the global shipping and logistics industry. Skou joined Maersk in 1983 and held various leadership roles within the company before becoming its CEO.  

Skou is the Vice Chairman of telecommunications equipment maker Nokia OY and Chairman of The Mærsk Mc-Kinney Møller Center for Zero Carbon Shipping. He holds an MBA with honors from IMD in Lausanne, Switzerland, and a graduate diploma in marketing from Copenhagen Business School.   

Søren Skou: 

“I look forward to joining the Board of Directors of Controlant next year. Controlant is at the heart of an incredibly exciting transformation of one of the world’s most critical supply chains—the pharmaceutical supply chain. Powered by digital, automated technology, logistics can have a significant impact in paving the way for efficient, safe, and sustainable delivery of medicine and vaccines to people around the world. A shared purpose to eliminate waste and ensure patient safety in pharma supply chains will drive the growth journey ahead.” 

Søren Skou joins as a Director on the Board of Controlant on 1 January 2024. 

Steve Van Kuiken 

Steve Van Kuiken brings a wealth of knowledge and insights from his tenure as a Senior Partner at McKinsey & Company. Over his long career at McKinsey, he founded and led the firm’s Healthcare Technology Practice. Leading the practice, he worked closely with CEOs and senior executives at the largest pharma companies globally on different aspects of digital transformations. Later Van Kuiken founded and built their technology transformation practice, McKinsey Technology, a fast-growing $2Bn global business. He also led McKinsey Digital for North America, and McKinsey’s alliance with Amazon Web Services. 

Van Kuiken has been a long-time leader in the life sciences practice, serving large, global pharmaceutical and medical product organizations. Prior to McKinsey, Steve was Vice President of IT at Baxter Healthcare and Senior Manager at Andersen Consulting. He has a B.A. in Economics and History from Hope College in Michigan in the United States.  

Steve Van Kuiken: 

“When it comes to healthcare and pharmaceuticals, there can be no compromise on quality and patient safety. I am honored to join the Board of Directors of Controlant, a company with a clear vision that unites and inspires its growing global team as well as customers. Having seen firsthand the impact that technology can have in propelling business forward and addressing some of the most pressing challenges we face, I am excited for the future of Controlant in enabling pharma supply chains to be the driver of safer, more equitable and sustainable global distribution of medicines and vaccines.” 

Steve Van Kuiken joins as Director of the Board of Controlant on 16 June 2023.  

The Board of Directors  

As of the 2023 Annual General Meeting, the Board of Directors is comprised of Ásthildur Otharsdóttir, Chairman, Jørgen Rugholm, Kristín Friðgeirsdóttir, Steve Van Kuiken, and Trausti Þórmundsson. 

Søren Skou and Jørgen Rugholm will share the term, with Rugholm on the Board until 1 January 2024 at which time he will step down and Skou will join the Board.